Potent inhibitors of LpxC for the treatment of Gram-negative infections.

@article{Brown2012PotentIO,
  title={Potent inhibitors of LpxC for the treatment of Gram-negative infections.},
  author={Matthew F. Brown and Usa Datta Reilly and Joseph A Abramite and Joel T Arcari and R. M. Oliver and Rose A Barham and Ye Che and Jinshan Michael Chen and Elizabeth M Collantes and Seung Won Chung and Charlene R Desbonnet and Jonathan L Doty and Matthew D Doroski and Juntyma J Engtrakul and Thomas M Harris and Michael D. Huband and John D. Knafels and Karen Leach and Shenping Liu and Anthony Marfat and Andrea de Oliveira Marques Marra and Eric B McElroy and Michael M Melnick and Carol A Menard and Justin I. Montgomery and Lisa M Mullins and Mark C. Noe and John P O'donnell and Joseph B Penzien and Mark S Plummer and Loren M Price and Veerabahu Shanmugasundaram and Christy L Thoma and Daniel P Uccello and Joseph S Warmus and Donn G. Wishka},
  journal={Journal of medicinal chemistry},
  year={2012},
  volume={55 2},
  pages={914-23}
}
In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid.